Indication name: Respiratory
syncytial virus (RSV)
Respiratory
syncytial virus (RSV) – Market outlook, Epidemiology, Market Forecast and
Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany,
France, Spain, United Kingdom, Italy, Japan & China)
Respiratory syncytial virus (RSV) is a
filamentous enveloped, negative-sense, single-stranded RNA virus that belongs
to the Orthopneumovirus genus of the Pneumoviridae family in the order
Mononegavirales. This family also contains human metapneumovirus (hMPV), which
belongs to the Metapneumovirus genus and, like RSV, is a major pathogen in
children. The symptoms of RSV and hMPV infection are indistinguishable, and
both are generally transmitted through close contact.
Epidemiology-
According to Thelansis disease modeling data, results of literature reviews,
and surveys estimated in the United States, nearly all children become infected
with RSV by age 2, with 95,000 to 135,000 of them hospitalized each year.
Approximately 0.5% to 2.0% of all children are hospitalized with lower
respiratory tract disease, of which 50% to 90% face bronchiolitis and 5% to 40%
encounter pneumonia. Globally, RSV affects an estimated 64 million people and
causes 160,000 deaths each year.
Competitive landscape of Respiratory syncytial virus (RSV) includes country
specific approved as well as pipeline therapies. Any asset/ product specific
designation or review and Accelerated Approval are being tracked and
supplemented with analyst commentary.
KOLs insights of Respiratory syncytial virus (RSV) 8 MM market from center of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm and Unmet needs.
Respiratory syncytial virus (RSV) market forecast: Patient Based Forecast Model
(MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market
Event and Product Event, Country specific Forecast Model, Market uptake and
patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and
pricing scenario, Summary and Insights.
Read more: Respiratory syncytial virus (RSV) – Market
outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020
To 2030
S. No Asset Company Stage
1 GSK3844766A GlaxoSmithKline Phase 2
2 ALN-RSV01 Alnylam Pharmaceuticals Phase 2
3 EDP-938 Enanta Pharmaceuticals Phase 2
4 Presatovir Gilead Sciences Phase 2
5 PC786 Pulmocide Ltd Phase 2
6 MEDI8897 MedImmune LLC Phase 3
7 ALS-008176 Alios Biopharma Inc. Phase 1
8 MV-012-968 Meissa Vaccines, Inc. Phase 1
9 CodaVax-RSV Codagenix, Inc Phase 1
10 MVA-mBN294B Bavarian Nordic Phase 2
No comments:
Post a Comment